FDA Enforcement Priorities: Eye Products, Dual Drug/Cosmetic Firms

摘要

Cosmetics firms that market products used in and around the eye and firms that also manufacture drugs are more likely targets for FDA inspections and enforcement action, according to Karyn Campbell, director of the investigations branch at the agency's Philadelphia District Office. Drug firms are typically allotted a "higher risk status," the exec said during an Oct. 3 presentation at the Personal Care Product Council's Scientific Symposium in Newark, N.J. When FDA inspects a facility producing both drugs and cosmetics, the manufacturer should be "using one standard and that's the drug standard," Campbell explained.